Pharmaron Beijing Co., Ltd.

HKSE 3759.HK

Pharmaron Beijing Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 25.54%

Pharmaron Beijing Co., Ltd. EBITDA Margin is 25.54% for the year ending December 31, 2023, a 3.66% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Pharmaron Beijing Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 24.64%, a -26.39% change year over year.
  • Pharmaron Beijing Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 33.48%, a 0.01% change year over year.
  • Pharmaron Beijing Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 33.47%, a 21.78% change year over year.
  • Pharmaron Beijing Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 27.49%, a 14.10% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
SV Wall Street
HKSE: 3759.HK

Pharmaron Beijing Co., Ltd.

CEO Dr. Boliang Lou Ph.D.
IPO Date Nov. 28, 2019
Location China
Headquarters 6 Taihe Road
Employees 20,295
Sector Healthcare
Industries
Description

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Similar companies

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 2.31

0.10%

3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

USD 3.68

2.50%

1801.HK

Innovent Biologics, Inc.

USD 4.60

8.31%

StockViz Staff

February 8, 2025

Any question? Send us an email